MedWatch

Novo Nordisk enters into collaboration with Danish crispr firm Snipr

The small Danish biotech company Snipr Biome, which uses crispr technology, has landed its first partnership.

Photo: Novo Nordisk / PR

Shortly after Snipr Biome managed to bring in new money through its first non-commercial partnership with antimicrobial alliance Carb-X, the Danish company has now managed to find its first commercial partner.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs